Acted as Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker
Panmure Gordon is delighted to announce that it has acted as Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker to Allergy Therapeutics plc on an unconditional mandatory cash offer by its shareholder, ZQ Capital, which valued the company at £48 million.
Allergy Therapeutics plc is an integrated commercial biotechnology company specialising in allergy vaccines.
Managing Director, Healthcare, Investment Banking
Managing Director, Corporate Broking Services
Vice President, Investment Banking, IBD Advisory
Managing Director, Head of Healthcare
Analyst, Investment Banking
Dr Mike Mitchell
Director, Research Analyst, Healthcare